Advertisement

ASCO 2020

ASCO: Larotrectinib Produces Durable Responses

TRK fusion targets multiple cancers Patients diagnosed with a variety of advanced cancers — from thyroid to breast cancer — appear to have durable responses when treated with larotrectinib (Vitrakvi), an agent that...

Read More

Advertisement

For latest news and updates
Email-id is invalid

Meeting Coverage